<?xml version='1.0' encoding='utf-8'?>
<document id="23754575"><sentence text="CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies." /><sentence text="Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells"><entity charOffset="82-105" id="DDI-PubMed.23754575.s2.e0" text="monomethyl auristatin E" /><entity charOffset="107-111" id="DDI-PubMed.23754575.s2.e1" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.23754575.s2.e0" e2="DDI-PubMed.23754575.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23754575.s2.e0" e2="DDI-PubMed.23754575.s2.e1" /></sentence><sentence text=" This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE"><entity charOffset="117-120" id="DDI-PubMed.23754575.s3.e0" text="MMAE" /></sentence><sentence text=" Two 21-day cycles of brentuximab vedotin (1" /><sentence text="2 or 1" /><sentence text="8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies" /><sentence text=" Each patient also received either a sensitive CYP3A substrate (midazolam), an effective inducer (rifampin), or a strong inhibitor (ketoconazole)"><entity charOffset="64-73" id="DDI-PubMed.23754575.s7.e0" text="midazolam" /><entity charOffset="98-106" id="DDI-PubMed.23754575.s7.e1" text="rifampin" /><entity charOffset="132-144" id="DDI-PubMed.23754575.s7.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23754575.s7.e0" e2="DDI-PubMed.23754575.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23754575.s7.e0" e2="DDI-PubMed.23754575.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23754575.s7.e0" e2="DDI-PubMed.23754575.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23754575.s7.e1" e2="DDI-PubMed.23754575.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23754575.s7.e1" e2="DDI-PubMed.23754575.s7.e2" /></sentence><sentence text=" Brentuximab vedotin did not affect midazolam exposures" /><sentence text=" ADC exposures were unaffected by concomitant rifampin or ketoconazole; however, MMAE exposures were lower with rifampin and higher with ketoconazole"><entity charOffset="46-54" id="DDI-PubMed.23754575.s9.e0" text="rifampin" /><entity charOffset="58-70" id="DDI-PubMed.23754575.s9.e1" text="ketoconazole" /><entity charOffset="112-120" id="DDI-PubMed.23754575.s9.e2" text="rifampin" /><entity charOffset="137-149" id="DDI-PubMed.23754575.s9.e3" text="ketoconazole" /><entity charOffset="81-92" id="DDI-PubMed.23754575.s9.e4" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e0" e2="DDI-PubMed.23754575.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e0" e2="DDI-PubMed.23754575.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e0" e2="DDI-PubMed.23754575.s9.e4" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e0" e2="DDI-PubMed.23754575.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e0" e2="DDI-PubMed.23754575.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e1" e2="DDI-PubMed.23754575.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e1" e2="DDI-PubMed.23754575.s9.e4" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e1" e2="DDI-PubMed.23754575.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e1" e2="DDI-PubMed.23754575.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e4" e2="DDI-PubMed.23754575.s9.e4" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e4" e2="DDI-PubMed.23754575.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e4" e2="DDI-PubMed.23754575.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e2" e2="DDI-PubMed.23754575.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23754575.s9.e2" e2="DDI-PubMed.23754575.s9.e3" /></sentence><sentence text=" The short-term safety profile of brentuximab vedotin in this study was generally consistent with historic clinical observations" /><sentence text=" The most common adverse events were nausea, fatigue, diarrhea, headache, pyrexia, and neutropenia" /><sentence text=" Over a 1-week period, ∼23" /><sentence text="5% of intact MMAE was recovered after administration of brentuximab vedotin; all other species were below the limit of quantitation"><entity charOffset="13-16" id="DDI-PubMed.23754575.s13.e0" text="MMAE" /></sentence><sentence text=" The primary excretion route is via feces (median 72% of the recovered MMAE)"><entity charOffset="71-74" id="DDI-PubMed.23754575.s14.e0" text="MMAE" /></sentence><sentence text=" These results suggest that brentuximab vedotin (1" /><sentence text="8 mg/kg) and MMAE are neither inhibitors nor inducers of CYP3A; however, MMAE is a substrate of CYP3A"><entity charOffset="13-16" id="DDI-PubMed.23754575.s16.e0" text="MMAE" /><entity charOffset="73-76" id="DDI-PubMed.23754575.s16.e1" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.23754575.s16.e0" e2="DDI-PubMed.23754575.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23754575.s16.e0" e2="DDI-PubMed.23754575.s16.e1" /></sentence><sentence text="" /></document>